Polyrizon Completes Branding Process for PL-14 Allergy Blocker as NASARIX™
Raanana, Israel, January 08, 2026 - Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical stage biotechnology company focused on developing innovative intranasal protective solutions, has announced the completion of its branding process for the PL-14 allergy blocker. The product will be marketed under the brand name NASARIX™.
Overview of NASARIX™
NASARIX™is formulated using Polyrizon’s proprietary Capture and Contain™ (C&C) hydrogel technology. This advanced intranasal spray creates a protective barrier designed to block exposure to allergens and viruses. The introduction of the NASARIX™ brand marks a significant milestone in Polyrizon's efforts aimed at future commercialization.
Importance of the Branding Process
The branding initiative involved extensive trademark screenings and linguistic evaluations in both U.S. and European markets to ensure brand viability and regulatory compliance. This strategic move supports Polyrizon's capability to effectively communicate the unique benefits of NASARIX™ to patients, healthcare professionals, and commercial partners.
Statements from Leadership
"Selecting NASARIX™ as the brand name for our PL-14 allergy blocker reflects our commitment to commercial readiness and our focus on building a strong and recognizable identity in the allergy and respiratory health markets," stated Tomer Izraeli, CEO of Polyrizon. "This is a key step as we advance toward upcoming clinical and regulatory milestones."
Looking Ahead: Clinical and Regulatory Pathways
Polyrizon anticipates that NASARIX™ will be launched in conjunction with the company's ongoing clinical advancements and regulatory processes. The successful branding of NASARIX™ is seen as an essential step toward the company's future in the biotechnology space, particularly in addressing allergy and respiratory health concerns.
About Polyrizon
Polyrizon is at the forefront of developing innovative medical device hydrogels administered via nasal sprays, providing a protective barrier against viruses and allergens. Its proprietary technology, captured in the Capture and Contain™ hydrogel, employs naturally occurring components to deliver a “biological mask” effect. Additionally, the company is exploring further applications through its Trap and Target™ (T&T) technology, aimed at effectively delivering active pharmaceutical ingredients via nasal routes.
For more information on Polyrizon's advancements and products, please visit polyrizon-biotech.com.
Forward Looking Statements
This communication contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Such statements include anticipated outcomes regarding the commercialization of NASARIX™, clinical development milestones, and other future developments. Readers should be aware that results may differ significantly from those projected, due to inherent uncertainties associated with such forward-looking statements.